IMG enters the post-earnings period in an unusual position: it just delivered one of its strongest quarterly results in years, yet the stock has lost ground on the week.
Q1 2026 was a blowout. Revenue hit $1.031 billion — 6% ahead of estimates — and adjusted EPS of $0.67 cleared the $0.53 consensus by a wide margin. Net income reached $380 million, nearly ten times the year-ago figure. Mine-site free cash flow came in at $525 million. CEO Renaud Adams called it the start of "one of the most catalyst-rich periods in company history," pointing to updated technical reports due across all four assets over the next 12 to 18 months. The share buyback program has already returned $350 million to shareholders since December.
The borrow market told an interesting story heading into the print. Cost to borrow spiked sharply in the days before the release — touching 2.0% on April 30, then jumping to 1.97% on May 1, roughly three times the mid-April level of around 0.53%. That compression reversed fast: borrowing costs have since tumbled back to 0.77%, down 33% on the week and 68% over the month. Availability in the lending pool is very loose — the stock's short interest is less than 1% of free float at 0.75%, a trivially small short position. The borrow spike looks like opportunistic hedging ahead of the number rather than a structural bear thesis building. With the print now out, the pressure has unwound.
Short interest itself is not a meaningful story here. The 0.75% of free float is well within normal territory for a mid-cap gold producer, even accounting for the 21% month-on-month rise in shares short — in absolute terms, that adds up to fewer than 900,000 additional shares in a company with hundreds of millions outstanding. The ORTEX short score has been drifting lower all week, from 28.2 on April 28 to 26.9 on May 5, reflecting a mild easing of short-side conviction. Days to cover stands at 2.5 on the official FINRA count. None of this signals meaningful short pressure.
Institutional ownership is a more interesting angle. Van Eck Associates holds 7.8% of shares, making it the largest declared holder — a natural position given the firm's gold-focused ETF complex. Fidelity International added aggressively, building a 6.2% stake that included a 20 million share increase in the December quarter. FMR (Fidelity US) added nearly 11 million shares through March 31. Sprott added just over 1 million shares in the same period. The broad direction of institutional flow over the past two quarters has been accumulative, not distributive. Meanwhile, insider activity from March shows CEO Adams sold roughly 83,000 shares at around C$31 — a clean market-price disposal, now at a premium to the current C$22.16, reflecting the stock's 17% pullback over the past month.
Valuation multiples have re-rated sharply lower alongside the price drop. The price-to-book has fallen to 1.47, down 0.31 over the past 30 days. The P/E multiple has contracted to 7.2x, sliding 1.4 points over the same period. EV/EBITDA is 3.9x. For context, the company generated over $2 billion in EBITDA over the trailing twelve months by its own account, yet the enterprise value implied by those multiples is modest. The EV/EBIT factor score ranks in the 94th percentile across the ORTEX universe — a signal that the market is ascribing a low multiple relative to operating earnings. The short score percentile rank of 87 reflects that shorts are not particularly active relative to the universe, consistent with the raw data.
Close peers have had a rough week across the board. CG fell 7.1% on the week, AEM shed 5.9%, and DPM dropped 6.8%. IMG is down 1.7% on the week — a relative outperformance that likely reflects the earnings beat providing a near-term floor. Whether the Q1 results are enough to reverse the month-long drawdown, or whether broader gold-sector weakness continues to drag on the name, is the question the market will be answering over the coming sessions.
See the live data behind this article on ORTEX.
Open IMG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
